Research programme: epigenetic therapeutics - Constellation Pharmaceuticals

Drug Profile

Research programme: epigenetic therapeutics - Constellation Pharmaceuticals

Alternative Names: CPI-169; CPI-203; CPI-232; CPI-267203; CPI-360; EZH2 inhibitors - Constellation Pharmaceuticals; Inhibitors of BET family of bromodomain-containing proteins - Constellation Pharmaceuticals; Inhibitors of histone methyltransferase - Constellation Pharmaceuticals

Latest Information Update: 22 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Constellation Pharmaceuticals
  • Developer Constellation Pharmaceuticals; Genentech; University of Pittsburgh
  • Class Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors; Histone deacetylase inhibitors; Histone methyltransferase inhibitors; Ubiquitin-protein ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Cystic fibrosis; Haematological malignancies
  • Research Immunological disorders; Inflammation; Multiple myeloma

Most Recent Events

  • 10 Oct 2013 Preclinical trials in Cystic fibrosis in USA (unspecified route)
  • 11 Sep 2013 Early research in Inflammation, immunological disorders and multiple myeloma is ongoing in USA
  • 20 Sep 2012 Constellation Pharmaceuticals enters partnership to co-develop a small-molecule, bromodomain and extra-terminal (BET) inhibitor in USA for Haematological malignancies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top